2024
Autosomal Dominant Polycystic Kidney Disease
Suarez M, Titan S, Dahl N. Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2024, 31: 496-503. PMID: 39577883, DOI: 10.1053/j.akdh.2024.07.003.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDelivery of personalized treatmentKidney diseaseKidney failureMinority of patientsDominant polycystic kidney diseaseEnd-stage kidney diseaseRisk of kidney failureCause of end-stage kidney diseasePolycystic kidney diseaseBlood pressure managementMassive hepatomegalySevere complicationsPolycystic liverIntracranial aneurysmsPersonalized treatmentNatural historyOrgan systemsDiseaseTreatmentKidneyPressure managementLiverSystem conditionsPreimplantationTolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18–35 Years: A Pooled Database Analysis
Chebib F, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18–35 Years: A Pooled Database Analysis. Kidney Medicine 2024, 100935. DOI: 10.1016/j.xkme.2024.100935.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseMedian follow-upEGFR decline rateFollow-upEGFR declineIncreased risk of rapid progressionAutosomal dominant polycystic kidney disease patientsKidney failureRisk of rapid progressionStandard of care treatmentBenefits of tolvaptanTolvaptan-treated patientsChronic kidney disease stageEfficacy of tolvaptanPolycystic kidney disease progressionEffect of tolvaptanAutosomal dominant polycystic kidney disease progressionKidney disease stageDominant polycystic kidney diseaseLong-term efficacyFollow-up periodKidney disease progressionMayo imaging classificationPolycystic kidney diseaseMixed-effects models
2023
The VUS Challenge in Cystic Kidney Disease: A Case-Based Review
Aklilu A, Gulati A, Kolber K, Yang H, Harris P, Dahl N. The VUS Challenge in Cystic Kidney Disease: A Case-Based Review. Kidney360 2023, 5: 152-159. PMID: 37962562, PMCID: PMC10833605, DOI: 10.34067/kid.0000000000000298.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseKidney diseaseHigh pre-test probabilityGenetic testingCase-based reviewPre-test probabilityDominant polycystic kidney diseaseRoutine genetic testingPost-test genetic counselingCystic kidney diseasePolycystic kidney diseaseFurther family studiesNephrology clinicKidney failureClinical criteriaCystic disordersOrdering clinicianCommon causeAppropriate carePathogenic variantsACMG guidelinesClinical settingDiagnostic groupingsUncertain significanceGenetic reportsDialysis Patient Experiences During the COVID-19 Pandemic: A Survey Study
Noce E, Brereton L, Zorzanello M, Aklilu A, Anders E, Bernal M, Sundararajan A, Dahl N, Kodali R, Patel D. Dialysis Patient Experiences During the COVID-19 Pandemic: A Survey Study. Kidney Medicine 2023, 5: 100673. PMID: 37305377, PMCID: PMC10186967, DOI: 10.1016/j.xkme.2023.100673.Peer-Reviewed Original ResearchCoronavirus disease 2019 (COVID-19) pandemicMental health conditionsDisease 2019 pandemicCare teamPatient experienceCare experiencesMost patientsCenter hemodialysisKidney failureDialysis treatmentDialysis careCOVID-19 pandemicHealth conditionsDialysis care teamNon-white patientsSubpopulation of patientsCare of patientsPercent of participantsPatient care experiencesNephrology practicePatient's perspectiveDerive themesPatientsAbstractTextPractice settings
2021
IgA vasculitis complicated by acute kidney failure with thrombotic microangiopathy: successful use of eculizumab
Patel DM, Cantley L, Moeckel G, Dahl NK, Luciano R. IgA vasculitis complicated by acute kidney failure with thrombotic microangiopathy: successful use of eculizumab. Journal Of Nephrology 2021, 34: 2141-2145. PMID: 34019254, DOI: 10.1007/s40620-021-01028-8.Peer-Reviewed Original Research